|Drug Name||GPCR-targeted Project 003|
The RSPO family of four secreted glycoproteins (RSPO 1-4) acts as potent activators of the Wnt/β-catenin signaling pathway, which has been implicated in the development and growth of multiple tumor types, including ovarian, lung and pancreatic cancers. A humanized monoclonal antibody against RSPO3 is under development and showed potential immunostimulation and anti-tumor activity in preclinical studies.
|Target||R-spondin 3 (RSPO3)|
|Drug Modality||Monoclonal antibody|
|Mechanism of Action||RSPO3 antagonists|
We look forward to hearing from you.